CN104688705A - 一种α-硫辛酸缓释片及其制备方法 - Google Patents
一种α-硫辛酸缓释片及其制备方法 Download PDFInfo
- Publication number
- CN104688705A CN104688705A CN201510068008.6A CN201510068008A CN104688705A CN 104688705 A CN104688705 A CN 104688705A CN 201510068008 A CN201510068008 A CN 201510068008A CN 104688705 A CN104688705 A CN 104688705A
- Authority
- CN
- China
- Prior art keywords
- alpha
- lipoic acid
- slow releasing
- releasing tablet
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 title claims abstract description 318
- 235000019136 lipoic acid Nutrition 0.000 title claims abstract description 172
- 229960002663 thioctic acid Drugs 0.000 title claims abstract description 172
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000007939 sustained release tablet Substances 0.000 title abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 40
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims abstract description 39
- 239000007888 film coating Substances 0.000 claims abstract description 31
- 238000009501 film coating Methods 0.000 claims abstract description 31
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 20
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 16
- 239000007779 soft material Substances 0.000 claims abstract description 10
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000011248 coating agent Substances 0.000 claims abstract description 4
- 238000000576 coating method Methods 0.000 claims abstract description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 29
- -1 hydroxypropyl Chemical group 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 244000248349 Citrus limon Species 0.000 claims description 10
- 235000005979 Citrus limon Nutrition 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 10
- 229910052782 aluminium Inorganic materials 0.000 claims description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- 239000004408 titanium dioxide Substances 0.000 claims description 10
- 235000013312 flour Nutrition 0.000 claims description 6
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 229920000178 Acrylic resin Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003826 tablet Substances 0.000 abstract description 119
- 238000001035 drying Methods 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 5
- 230000002349 favourable effect Effects 0.000 abstract description 3
- 239000001913 cellulose Substances 0.000 abstract 3
- 229920002678 cellulose Polymers 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 2
- 238000007873 sieving Methods 0.000 abstract 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 33
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 28
- 229940079593 drug Drugs 0.000 description 25
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 18
- 239000008101 lactose Substances 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 17
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 238000009825 accumulation Methods 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229920003134 Eudragit® polymer Polymers 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 4
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960000346 gliclazide Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510068008.6A CN104688705B (zh) | 2015-02-09 | 2015-02-09 | 一种α‑硫辛酸缓释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510068008.6A CN104688705B (zh) | 2015-02-09 | 2015-02-09 | 一种α‑硫辛酸缓释片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104688705A true CN104688705A (zh) | 2015-06-10 |
CN104688705B CN104688705B (zh) | 2017-07-25 |
Family
ID=53336537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510068008.6A Active CN104688705B (zh) | 2015-02-09 | 2015-02-09 | 一种α‑硫辛酸缓释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104688705B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110420193A (zh) * | 2019-09-04 | 2019-11-08 | 西安科力康医药科技有限公司 | 一种α-硫辛酸缓控释片制备方法 |
CN111053758A (zh) * | 2018-10-17 | 2020-04-24 | 江苏恒正合生命科学有限公司 | 一种75%的alpha硫辛酸及其微囊化加工工艺 |
CN113181129A (zh) * | 2020-01-14 | 2021-07-30 | 亚宝药业集团股份有限公司 | 一种稳定的硫辛酸片的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1370072A (zh) * | 1999-01-13 | 2002-09-18 | 锡德克斯公司 | 以磺基烷基醚环糊精为基础的控释固体药物制剂 |
CN1868463A (zh) * | 2006-06-15 | 2006-11-29 | 南方医科大学珠江医院 | 一种α-硫辛酸或其衍生物的缓释制剂及其制备方法 |
WO2007138022A2 (en) * | 2006-05-25 | 2007-12-06 | Eurand Pharmaceuticals Limited | Lipoic acid pellets |
CN102469807A (zh) * | 2009-07-14 | 2012-05-23 | 希尔氏宠物营养品公司 | 包括持续释放的硫辛酸的宠物食品组合物及其制造和使用方法 |
-
2015
- 2015-02-09 CN CN201510068008.6A patent/CN104688705B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1370072A (zh) * | 1999-01-13 | 2002-09-18 | 锡德克斯公司 | 以磺基烷基醚环糊精为基础的控释固体药物制剂 |
WO2007138022A2 (en) * | 2006-05-25 | 2007-12-06 | Eurand Pharmaceuticals Limited | Lipoic acid pellets |
CN1868463A (zh) * | 2006-06-15 | 2006-11-29 | 南方医科大学珠江医院 | 一种α-硫辛酸或其衍生物的缓释制剂及其制备方法 |
CN102469807A (zh) * | 2009-07-14 | 2012-05-23 | 希尔氏宠物营养品公司 | 包括持续释放的硫辛酸的宠物食品组合物及其制造和使用方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111053758A (zh) * | 2018-10-17 | 2020-04-24 | 江苏恒正合生命科学有限公司 | 一种75%的alpha硫辛酸及其微囊化加工工艺 |
CN110420193A (zh) * | 2019-09-04 | 2019-11-08 | 西安科力康医药科技有限公司 | 一种α-硫辛酸缓控释片制备方法 |
CN113181129A (zh) * | 2020-01-14 | 2021-07-30 | 亚宝药业集团股份有限公司 | 一种稳定的硫辛酸片的制备方法 |
CN113181129B (zh) * | 2020-01-14 | 2022-07-22 | 亚宝药业集团股份有限公司 | 一种稳定的硫辛酸片的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104688705B (zh) | 2017-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101483203B1 (ko) | 무정형 cddo-me를 포함하는, 지연 방출형 경구 투여 조성물 | |
JP2008156374A (ja) | 持続放出性製剤 | |
CN106420808B (zh) | 一种含有维生素d3和碳酸钙的制剂及其制备方法 | |
CN110037994A (zh) | 一种布洛芬速释缓释双层片及其制备方法 | |
CN110115384A (zh) | 维生素c组合物和制备维生素c包衣缓释片的方法及维生素c包衣缓释片 | |
CN104688705A (zh) | 一种α-硫辛酸缓释片及其制备方法 | |
JP2812909B2 (ja) | フラボノ−リグナン調剤の製造法、この種の調剤、該調剤を含有する医薬品および該医薬品の製造法 | |
JP7007300B2 (ja) | ダパグリフロジンの新規な結晶形並びにその製造方法および用途 | |
EP1686966B1 (fr) | Comprimes faiblement doses a reseau de polymeres | |
CN106138059A (zh) | 一种稳定的利格列汀药物组合物 | |
CN106619646B (zh) | 一种替吉奥组合物的制备方法 | |
KR101269665B1 (ko) | 카르두스 마리아누스 엑스, 및 쿠르쿠마 잔토리자 엑스를 포함하는 필름코팅정, 및 이의 제조방법 | |
CN101836981B (zh) | 复方缬沙坦苯磺酸氨氯地平药物组合物及其制备方法 | |
CN104138363B (zh) | 一种硝苯地平缓释片及其制备方法 | |
CN1785239A (zh) | 一种复方丹参缓释制剂及其制备方法 | |
CN104398482B (zh) | 应用复合乳糖的吲达帕胺缓释药物 | |
CN102038661B (zh) | 齐墩果酸渗透泵片及其制备方法 | |
WO2022141429A1 (zh) | 一种含有活性肽、有机钙的氨糖软骨素片剂及其制备方法 | |
CN102688211B (zh) | 一种左卡尼汀渗透泵缓、控释片及其制备方法 | |
CN107550881B (zh) | 一种非洛地平缓释片及其制备工艺 | |
CN117017921B (zh) | 一种人参皂苷脂质体及其制备方法 | |
CN104644601B (zh) | 一种卡培他滨片剂 | |
CN113521022B (zh) | 一种含有伊来西胺的缓释片及其制备方法 | |
CN104138365A (zh) | 一种替米沙坦胶囊剂及其制备方法 | |
CN108904465A (zh) | 一种布洛芬药物制剂组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240226 Address after: Room 212, 2nd Floor, Building 4, No. 108 Yuxin Road, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province, 215000 Patentee after: Suzhou Boyan Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: No. 166 Gaoxin Avenue, Donghu New District, Wuhan City, Hubei Province, 430079 Patentee before: WUHAN ZEZHI BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Country or region before: China |